OBJECTIVE: To develop a preliminary power Doppler (PD) US composite score for global assessment of PsA patients. METHODS: Sixteen PsA patients receiving anti-TNF-α therapy were enrolled. All patients were involved in multiple psoriatic targets, including joints, tendon, enthesis, skin and nail. The target with the highest PD signal, one for each target area, was selected to be scanned at baseline and at follow-up visit 8 weeks after. For each target, PD was graded according to semi-quantitative scoring systems. Inter- and intra-observer reliability and feasibility was also investigated. The new PD composite score for PsA was called Five Targets PD for Psoriatic Disease (5TPD). RESULTS: Sixty targets (16 joints, 9 tendons, 11 enthesis, 16 psoriatic plaques and 8 psoriatic onychopathies) were assessed. A significant improvement of the clinical scores was found at follow-up with respect to the baseline: HAQ modified for SpA (HAQ-S) (P = 0.0001); Psoriasis Area and Severity Index (P = 0.0001) and Nail Psoriasis Severity Index (P = 0.35). The 5TPD showed a significant change between baseline and follow-up (P = 0.0001). There was no significant correlation between HAQ-S and 5TPD findings. The inter- and intra-observer κ-values varied from good to excellent at baseline and follow-up. The time spent on baseline US examinations was mean (s.d.) 10.5 (2.0) min and no more than 7 min for follow-up assessment. CONCLUSION: The present study provides a new working hypothesis that the sonographic core set may be useful to construct a PDUS composite score for the assessment of PsA. The 5TPD formula provides a feasible and reliable approach for multi-target monitoring of psoriatic disease.
OBJECTIVE: To develop a preliminary power Doppler (PD) US composite score for global assessment of PsA patients. METHODS: Sixteen PsA patients receiving anti-TNF-α therapy were enrolled. All patients were involved in multiple psoriatic targets, including joints, tendon, enthesis, skin and nail. The target with the highest PD signal, one for each target area, was selected to be scanned at baseline and at follow-up visit 8 weeks after. For each target, PD was graded according to semi-quantitative scoring systems. Inter- and intra-observer reliability and feasibility was also investigated. The new PD composite score for PsA was called Five Targets PD for Psoriatic Disease (5TPD). RESULTS: Sixty targets (16 joints, 9 tendons, 11 enthesis, 16 psoriatic plaques and 8 psoriatic onychopathies) were assessed. A significant improvement of the clinical scores was found at follow-up with respect to the baseline: HAQ modified for SpA (HAQ-S) (P = 0.0001); Psoriasis Area and Severity Index (P = 0.0001) and Nail Psoriasis Severity Index (P = 0.35). The 5TPD showed a significant change between baseline and follow-up (P = 0.0001). There was no significant correlation between HAQ-S and 5TPD findings. The inter- and intra-observer κ-values varied from good to excellent at baseline and follow-up. The time spent on baseline US examinations was mean (s.d.) 10.5 (2.0) min and no more than 7 min for follow-up assessment. CONCLUSION: The present study provides a new working hypothesis that the sonographic core set may be useful to construct a PDUS composite score for the assessment of PsA. The 5TPD formula provides a feasible and reliable approach for multi-target monitoring of psoriatic disease.
Authors: Christina Duftner; Christian Dejaco; Franz Kainberger; Klaus Machold; Peter Mandl; Thomas Nothnagl; Tobias DeZordo; Rusmir Husic; Claudia Schüller-Weidekamm; Michael Schirmer Journal: Wien Klin Wochenschr Date: 2014-10-02 Impact factor: 1.704
Authors: Marwin Gutierrez; Cristina Hernandez-Diaz; Lucio Ventura-Rios; Lina María Saldarriaga-Rivera; Santiago Ruta; Magaly Alva; Claudia Mora -Trujillo; Wilkerson Pérez; Henry Terrazas; Rodolfo Del Carmen Arape Toyo; Maritza Quintero; Carla Solano; Oscar Sedano Santiago; Janet Grisel Huamán Sotomayor; Cesar Cefferino; Guillermo E Py; Marcelo J Audisio; Walter Javier Spindler; Horacio Berman; Carla Airoldi; Rómulo Wong; Ana Laura Álvarez Del Castillo Araujo; Mario E Díaz; Carmen Cerón Villaquiran; Rubén Darío Mantilla; José Alexandre Mendonça; Inês Guimarães da Silveira; Aline Defaveri do Prado; Melissa Cláudia Bisi; Violeta Rosario; Jeannette Medrano-Sánchez; Roberto Muñoz-Louis; Ana Cecilia Lozada-Navarro; Araceli Bernal; Maribel Lozano; Carlos Pineda Journal: Clin Rheumatol Date: 2016-08-30 Impact factor: 2.980
Authors: Santiago Ruta; María Laura Acosta Felquer; Javier Rosa; David A Navarta; Ricardo García Monaco; Enrique R Soriano Journal: Clin Rheumatol Date: 2014-05-20 Impact factor: 2.980